Palisade Bio Names Sharon Skare as Vice President and Global Head of Clinical Operations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 28 2025
0mins
Should l Buy PALI?
Source: Newsfilter
Leadership Appointment: Palisade Bio has appointed Sharon Skare, PhD(c), as Vice President and Global Head of Clinical Operations, bringing over 24 years of experience in clinical development, particularly in autoimmune and gastrointestinal diseases.
Focus on PALI-2108: The company is advancing PALI-2108, a targeted oral therapy for ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 IND submission planned for the first half of 2026.
Clinical Development Strategy: PALI-2108 is designed for local delivery to the lower intestine, aiming to maximize therapeutic effects while minimizing systemic side effects, and has shown positive data in recent Phase 1 studies.
Company Vision: Palisade Bio aims to transform treatment for autoimmune and fibrotic diseases through innovative therapeutics, emphasizing the need for new therapies that balance efficacy and tolerability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PALI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PALI
Wall Street analysts forecast PALI stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.400
Low
7.00
Averages
13.00
High
25.00
Current: 2.400
Low
7.00
Averages
13.00
High
25.00
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palisade Bio Reports Early Trial Data for PALI-2108 in Crohn’s Disease
- Clinical Trial Progress: Palisade Bio reported two weeks of data from its early-stage trial of PALI-2108 for fibrostenotic Crohn’s disease, indicating endoscopic response rates comparable to AbbVie's Skyrizi and Rinvoq, highlighting its therapeutic potential.
- Safety Profile: The therapy showed no serious adverse events among five patients, and the experimental treatment was well tolerated, demonstrating its safety for clinical application.
- Follow-up Research Plans: Palisade Bio intends to launch a Phase 2 study to further evaluate PALI-2108's efficacy in moderate to severe Crohn’s disease patients, reflecting the company's confidence in the drug's future market potential.
- Market Outlook: Palisade Bio is viewed as an undervalued biotech firm with blockbuster drug development potential, leading to optimistic market sentiment regarding its future performance.
See More
Palisade Bio to Participate in Immunology Symposium
- Virtual Fireside Chat: Palisade Bio will participate in the Piper Sandler Virtual Immunology Symposium on February 12, 2026, from 1:30 PM to 1:55 PM ET, featuring CEO JD Finley and CMO Dr. Mitchell Jones discussing the company's innovations in immunology.
- PALI-2108 Drug Development: PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon, aimed at improving pharmacology and tolerability for patients with inflammatory and fibrotic diseases.
- Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics consistent with localized activation.
- Future Research Plans: The company is advancing towards a Phase 2 clinical study for PALI-2108, designed to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
- Strengthened Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, effective until 2041, which enhances the company's intellectual property foundation in the inflammatory bowel disease (IBD) sector, potentially boosting market competitiveness.
- Accelerated Clinical Progress: The ongoing development of PALI-2108 for UC and FSCD is on track, with an IND submission to the FDA planned for the first half of 2026, which, if successful, will provide more effective treatment options for patients and meet market demand.
- Significant Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in UC patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which may enhance market acceptance.
- Substantial Market Potential: Japan represents one of the largest markets for IBD globally, and the patent protection along with clinical advancements for PALI-2108 will help the company capture long-term growth opportunities in the region while improving patient outcomes.
See More
Bolt Projects Raises FY2026 Sales Guidance to $11 Million
- Sales Guidance Increase: Bolt Projects raised its FY2026 sales guidance from $9 million to $11 million, reflecting the company's confidence in future growth, which is likely to attract more investor interest.
- Fourth Quarter Sales Forecast: The company anticipates fourth-quarter sales of $2.7 million, and this positive outlook may further drive stock price increases, enhancing market confidence.
- Strong Stock Price Reaction: Bolt Projects' shares surged 28.2% to $1.73 in pre-market trading, indicating a bullish market sentiment towards the company's prospects, potentially drawing in more institutional investors.
- Market Dynamics Impact: The strong performance of Bolt Projects contrasts sharply with the volatility of other stocks, highlighting its relative strength in the current market environment, which may enhance its competitive position within the industry.
See More
Palisade Bio Reports Early Trial Data for PALI-2108 in Crohn’s Disease
- Clinical Trial Progress: Palisade Bio reported two weeks of data from its early-stage trial of PALI-2108 for fibrostenotic Crohn’s disease, indicating endoscopic response rates comparable to AbbVie's Skyrizi and Rinvoq, highlighting its therapeutic potential.
- Safety Profile: The therapy showed no serious adverse events among five patients, and the experimental treatment was well tolerated, demonstrating its safety for clinical application.
- Follow-up Research Plans: Palisade Bio intends to launch a Phase 2 study to further evaluate PALI-2108's efficacy in moderate to severe Crohn’s disease patients, reflecting the company's confidence in the drug's future market potential.
- Market Outlook: Palisade Bio is viewed as an undervalued biotech firm with blockbuster drug development potential, leading to optimistic market sentiment regarding its future performance.
See More
Palisade Bio to Participate in Immunology Symposium
- Virtual Fireside Chat: Palisade Bio will participate in the Piper Sandler Virtual Immunology Symposium on February 12, 2026, from 1:30 PM to 1:55 PM ET, featuring CEO JD Finley and CMO Dr. Mitchell Jones discussing the company's innovations in immunology.
- PALI-2108 Drug Development: PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon, aimed at improving pharmacology and tolerability for patients with inflammatory and fibrotic diseases.
- Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics consistent with localized activation.
- Future Research Plans: The company is advancing towards a Phase 2 clinical study for PALI-2108, designed to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
- Strengthened Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, effective until 2041, which enhances the company's intellectual property foundation in the inflammatory bowel disease (IBD) sector, potentially boosting market competitiveness.
- Accelerated Clinical Progress: The ongoing development of PALI-2108 for UC and FSCD is on track, with an IND submission to the FDA planned for the first half of 2026, which, if successful, will provide more effective treatment options for patients and meet market demand.
- Significant Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in UC patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which may enhance market acceptance.
- Substantial Market Potential: Japan represents one of the largest markets for IBD globally, and the patent protection along with clinical advancements for PALI-2108 will help the company capture long-term growth opportunities in the region while improving patient outcomes.
See More
Bolt Projects Raises FY2026 Sales Guidance to $11 Million
- Sales Guidance Increase: Bolt Projects raised its FY2026 sales guidance from $9 million to $11 million, reflecting the company's confidence in future growth, which is likely to attract more investor interest.
- Fourth Quarter Sales Forecast: The company anticipates fourth-quarter sales of $2.7 million, and this positive outlook may further drive stock price increases, enhancing market confidence.
- Strong Stock Price Reaction: Bolt Projects' shares surged 28.2% to $1.73 in pre-market trading, indicating a bullish market sentiment towards the company's prospects, potentially drawing in more institutional investors.
- Market Dynamics Impact: The strong performance of Bolt Projects contrasts sharply with the volatility of other stocks, highlighting its relative strength in the current market environment, which may enhance its competitive position within the industry.
See More
